Direct oral anticoagulants (DOACs) demonstrate a lower risk–benefit ratio than vitamin K antagonists (VKAs) for secondary thromboprophylaxis of thrombotic events. But there are no data on the efficacy of DOACs for the prevention of thrombotic recurrence in patients with antiphospholipid syndrome (APS). In this study, we evaluated the efficacy of DOACs to prevent recurrences of thrombotic events in patients with APS.
Methods
This was a single-center pilot, using a multi-step Fleming design. If seven or fewer patients presented treatment failure with rivaroxaban, the study could conclude efficacy.
Results
A total of 23 patients were included. APS involved the veins only (n = 19), arteries only (n = 2) or both (n = 1) and 1 patient exhibited catastrophic antiphospholipid syndrome (CAPS). Overall, two patients were positive for lupus anticoagulant, anti-beta-2 glycoprotein I antibodies and anticardiolipid antibodies (triple positivity). The mean duration of follow up was 35.6 (range, 29–40) months. A total of six treatment failures were reported: one patient, with triple positivity, developed bilateral distal pulmonary embolism (PE) after 20 months of treatment with rivaroxaban, two patients refused to take rivaroxaban, the treatment was stopped in three other patients: two with adverse effects and one with chronic iron-deficiency anemia.
Conclusions
Rivaroxaban may represent an alternative for secondary thromboprophylaxis for thrombo-embolism in patients with APS, in particular, those with poor international normalized ratio (INR) control and those who are not at the highest risk of recurrent thrombosis, such as those with triple positivity.
MiyakisSLockshinMDAtsumiTet al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
ErkanDAguiarCLAndradeDet al.14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev2014; 13: 685–696.
3.
CrowtherMAGinsbergJSJulianJet al.A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med2003; 349: 1133–1138.
4.
FinazziGMarchioliRBrancaccioVet al.A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost2005; 3: 848–853.
5.
Da SilvaFFCarvalhoJF. Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis. Rev Bras Reumatol2015; 55: 159–166.
6.
CrowlASchullo-FeulnerAMoonJY. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother2014; 48: 1479–1483.
7.
EINSTEIN Investigators. BauersachsRBerkowitzSDet al.Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med2010; 363: 2499–2510.
8.
EINSTEIN Investigators. BüllerHRPrinsMHet al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med2012; 366: 1287–1297.
9.
BüllerHRDécoususHet al.Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med2013; 369: 1406–1415.
10.
AgnelliGBullerHRCohenAet al.Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med2013; 369: 799–808.
11.
SchulmanSKearonCKakkarAKet al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med2009; 361: 2342–2352.
12.
ArachchillageDJCohenH. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep2013; 15: 331–331.
13.
MoerloosePReberGMusialJArnoutJ. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost2010; 8: 1540–1506.
14.
FontanaPPoncetALindhoff-LastEet al.Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J Thromb Haemost2014; 12: 2034–2037.
15.
PengoVTripodiAReberGet al.Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost2009; 7: 1737–1737.
16.
RatainMJSargentDJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer2009; 45: 275–280.
17.
LimWCrowtherMAEikelboomJW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA2006; 295: 1050–1057.
18.
CohenHHuntBEfthymiouMet al.Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non inferiority trial. Lancet Haematol2016; 3: 426–436.
19.
NoelNDutastaFCostedoat-ChalumeauNet al.Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev2015; 14: 680–685.
20.
SciasciaSSavinoSBreenKHuntBJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis Int J Haemost Thromb2015; 26: 476–477.
21.
SonMWypasekECelinska-LowenhoffMUndasA. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res2015; 135: 1035–1036.
22.
SchaeferJKMcBaneRDBlackDFWilliamsLNModerKGWysokinskiWE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost2014; 112: 947–950.
23.
WinKRodgersGM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol2014; 89: 1017–1017.
24.
SignorelliFNogueiraFDominguesVMarizHALevyRA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol2016; 35: 801–805.
25.
BetancurJFBonilla-AbadíaFHormazaAAJaramilloFJCañasCATobonGJ. Direct oral anticoagulants in antiphospholipid syndrome: a real-life case series. Lupus2016; 25: 658–662.
26.
CerveraRSerranoRPons-EstelGJet al.Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2015; 74: 1011–1018.
27.
PengoVRuffattiALegnaniCet al.Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost2010; 8: 237–242.
28.
PengoVBanzatoABisonEZoppellaroGPadayaltil JoseSDenasG. Efficacy and safety of Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in Antiphospholipid Syndrome (TRAPS) trial. Lupus2016; 25: 301–306.
29.
WollerSCStevensSMKaplanDAet al.Apixaban for the Secondary Prevention of Thrombosis Among Patients with Antiphospholipid Syndrome: study rationale and design (ASTRO-APS). Clin Appl thromb Haemost2016; 22: 239–247.
30.
PrinsMHBamberLCanoSJet al.Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res2015; 135: 281–288.
31.
PastoriDParrottoSVicarioTet al.Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. Atherosclerosis2016; 244: 48–50.
32.
BansilalSBloomgardenZHalperinJLet al.Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J2015; 170: 675–682, e8.
33.
SiegalDMCurnutteJTConnollySJet al.Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med2015; 373: 2413–2424.
34.
HaraTFukudaDTanakaKet al.Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis2015; 242: 639–646.
35.
MegaJLBraunwaldEWiviottSDet al.Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med2012; 366: 9–19.
36.
BerknerKLRungeKW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost2004; 2: 2118–2132.
37.
SchurgersLJJoosenIALauferEMet al.Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PloS One2012; 7: e43229–e43229.
38.
LevyRASignorelliF. Patient-health care provider relationship: how can it impact on APS (Hughes’ syndrome) adherence to treatment?Lupus2014; 23: 1265–1268.
